<code id='EC244C4477'></code><style id='EC244C4477'></style>
    • <acronym id='EC244C4477'></acronym>
      <center id='EC244C4477'><center id='EC244C4477'><tfoot id='EC244C4477'></tfoot></center><abbr id='EC244C4477'><dir id='EC244C4477'><tfoot id='EC244C4477'></tfoot><noframes id='EC244C4477'>

    • <optgroup id='EC244C4477'><strike id='EC244C4477'><sup id='EC244C4477'></sup></strike><code id='EC244C4477'></code></optgroup>
        1. <b id='EC244C4477'><label id='EC244C4477'><select id='EC244C4477'><dt id='EC244C4477'><span id='EC244C4477'></span></dt></select></label></b><u id='EC244C4477'></u>
          <i id='EC244C4477'><strike id='EC244C4477'><tt id='EC244C4477'><pre id='EC244C4477'></pre></tt></strike></i>

          
          WSS
          Allergan, Dom Smith/STAT

          It wasn’t supposed to work out this way for Brent Saunders.

          Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

          advertisement

          As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive